lansoprazole has been researched along with Headache in 10 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Headache: The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "As can be expected, headache was reported less frequently in this study compared with clinical trials with lansoprazole." | 9.10 | Determinants of headache in lansoprazole users in The Netherlands: results from a nested case-control study. ( Claessens, AA; Heerdink, ER; Lamers, CB; Leufkens, HG; van Eijk, JT, 2002) |
| "This study was undertaken to compare the efficacy of lansoprazole (LAN)-based triple therapy with that of RBC-based dual therapy in H pylori-infected patients with duodenal ulcer." | 9.09 | Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study. ( Belmonte, A; Cavaliere, C; Ciliberto, E; Fiocca, R; Frandina, C; Giglio, A; Luzza, F; Pallone, F; Saccà, N; Trimboli, V, 2001) |
| " In this open-label study, the effect of lansoprazole 30 mg qd and naproxen 500 mg bid on the pharmacokinetic profile of methotrexate was investigated." | 6.71 | Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis. ( Amer, F; Andhivarothai, N; Kukulka, MJ; Vakily, M, 2005) |
| "As can be expected, headache was reported less frequently in this study compared with clinical trials with lansoprazole." | 5.10 | Determinants of headache in lansoprazole users in The Netherlands: results from a nested case-control study. ( Claessens, AA; Heerdink, ER; Lamers, CB; Leufkens, HG; van Eijk, JT, 2002) |
| "This study was undertaken to compare the efficacy of lansoprazole (LAN)-based triple therapy with that of RBC-based dual therapy in H pylori-infected patients with duodenal ulcer." | 5.09 | Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study. ( Belmonte, A; Cavaliere, C; Ciliberto, E; Fiocca, R; Frandina, C; Giglio, A; Luzza, F; Pallone, F; Saccà, N; Trimboli, V, 2001) |
| " The most common adverse events of headache, diarrhea, and nausea have been reported in fewer than 5% of patients treated with lansoprazole or omeprazole." | 4.80 | Safety profile of the proton-pump inhibitors. ( Reilly, JP, 1999) |
| " In this open-label study, the effect of lansoprazole 30 mg qd and naproxen 500 mg bid on the pharmacokinetic profile of methotrexate was investigated." | 2.71 | Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis. ( Amer, F; Andhivarothai, N; Kukulka, MJ; Vakily, M, 2005) |
| "Lansoprazole is a H+." | 2.68 | Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group. ( Bardhan, KD; Brocklebank, D; Hawkey, CJ; Long, RG; Morgan, AG; Moules, IK; Wormsley, KG, 1995) |
| "To estimate the rates of common adverse events in patients treated with the proton pump inhibitors omeprazole, lansoprazole and pantoprazole in general practice in England." | 1.31 | The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. ( Dunn, NR; Freemantle, S; Martin, RM; Shakir, S, 2000) |
| "Lansoprazole was mostly prescribed in patients with reflux oesophagitis (55." | 1.30 | A prospective follow-up study of 5669 users of lansoprazole in daily practice. ( Claessens, A; Heerdink, E; Lamers, CB; Leufkens, H; van Eijk, J, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (40.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Woolley, AK | 1 |
| Hedger, NA | 1 |
| Veettil, RP | 1 |
| Kovacs, TO | 1 |
| Freston, JW | 1 |
| Haber, MM | 1 |
| Hunt, B | 1 |
| Atkinson, S | 1 |
| Peura, DA | 1 |
| Vakily, M | 1 |
| Amer, F | 1 |
| Kukulka, MJ | 1 |
| Andhivarothai, N | 1 |
| Bardhan, KD | 1 |
| Hawkey, CJ | 1 |
| Long, RG | 1 |
| Morgan, AG | 1 |
| Wormsley, KG | 1 |
| Moules, IK | 1 |
| Brocklebank, D | 1 |
| Sontag, SJ | 1 |
| Schnell, TG | 1 |
| Chejfec, G | 1 |
| Kurucar, C | 1 |
| Karpf, J | 1 |
| Levine, G | 1 |
| Leufkens, H | 1 |
| Claessens, A | 1 |
| Heerdink, E | 1 |
| van Eijk, J | 1 |
| Lamers, CB | 2 |
| Reilly, JP | 1 |
| Martin, RM | 1 |
| Dunn, NR | 1 |
| Freemantle, S | 1 |
| Shakir, S | 1 |
| Luzza, F | 1 |
| Giglio, A | 1 |
| Ciliberto, E | 1 |
| Belmonte, A | 1 |
| Cavaliere, C | 1 |
| Saccà, N | 1 |
| Frandina, C | 1 |
| Fiocca, R | 1 |
| Trimboli, V | 1 |
| Pallone, F | 1 |
| Claessens, AA | 1 |
| Heerdink, ER | 1 |
| van Eijk, JT | 1 |
| Leufkens, HG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-blinded, Placebo-controlled Pilot Study to Evaluate the Efficacy and Safety of Rebamipide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis (REPAIR)[NCT02755753] | Phase 4 | 143 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| A Phase I, Randomized, Double-blind, Placebo- and Positive-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of Multiple Oral Doses of H008 (Carenoprazan Hydrochloride Tablets) in Healthy Volunteers[NCT05050188] | Phase 1 | 24 participants (Actual) | Interventional | 2021-06-24 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for lansoprazole and Headache
| Article | Year |
|---|---|
Safety profile of the proton-pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Diarrhea; Drug Interactions; Gastric Muc | 1999 |
6 trials available for lansoprazole and Headache
| Article | Year |
|---|---|
Long-term efficacy of lansoprazole in preventing relapse of erosive reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Aged; Aged, 80 and over; Diarrhea; D | 2009 |
Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents | 2005 |
Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Double-Blind Method; Esophagitis, Peptic; Foll | 1995 |
Lansoprazole heals erosive reflux oesophagitis in patients with Barrett's oesophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Barrett Esophagus; Double-Blind Method; Enzyme Inhibitors; | 1997 |
Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Bismuth; Clarit | 2001 |
Determinants of headache in lansoprazole users in The Netherlands: results from a nested case-control study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Age Factors; Aged; Case-Control Studies; | 2002 |
3 other studies available for lansoprazole and Headache
| Article | Year |
|---|---|
Problem based review: The patient with a pyrexia of unknown origin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Anti-Inflammatory Agents; Aorta; Aor | 2013 |
A prospective follow-up study of 5669 users of lansoprazole in daily practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 1997 |
The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Adverse Drug Reaction Reporting Syst | 2000 |